Obinutuzumab
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 973 publications
Impact of afucosylation strategy on antibody function: a comparative study of glycoengineered anti-CD20 antibodies Obinutuzumab and Obinutuzumab beta.
Journal: mAbs
Published: April 13, 2026
Is Obinutuzumab the Answer to Primary Membranous Nephropathy Resistant to Rituximab?
Journal: Kidney international reports
Published: April 08, 2026
Positive results for obinutuzumab in SLE phase III trial.
Journal: Nature reviews. Rheumatology
Published: April 08, 2026
The role of monoclonal antibodies in the treatment of lupus nephritis.
Journal: Expert opinion on biological therapy
Published: April 07, 2026
Bilateral Serous Maculopathy Associated with Acalabrutinib Therapy in Chronic Lymphocytic Leukemia.
Journal: Retinal cases & brief reports
Published: April 01, 2026
CLO26-111: Treatment-Naïve CLL in Routine Care: Acalabrutinib Monotherapy Versus Acalabrutinib Plus Obinutuzumab.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 30, 2026
HSR26-228: BTK Inhibitor (Bruton Tyrosine Kinase Inhibitor) Plus Anti-CD20 Antibody Therapy Surpasses CIT (Chemoimmunotherapy) in Frontline CLL (Chronic Lymphocytic Leukemia) With Obinutuzumab Drives Deeper Remissions: A Meta-Analysis of Randomized Controlled Trials.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 30, 2026
Response Rate in CLL Patients Treated with Obinutuzumab - Single Centre Experience from University Clinic of Hematology, Skopje.
Journal: Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki)
Published: March 21, 2026
Obinutuzumab for membranous nephropathy: a systematic review using pooled case-level extraction analysis.
Journal: Acta clinica Belgica
Published: March 19, 2026
Association between anti-rituximab antibodies and treatment efficacy of rituximab in membranous nephropathy.
Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Published: March 13, 2026
Analysis of risk factors for infusion-related reactions in patients with B-cell lymphoma during obinutuzumab treatment.
Journal: Journal of chemotherapy (Florence, Italy)
Published: March 10, 2026
Obinutuzumab (Gazyva) for lupus nephritis.
Journal: The Medical letter on drugs and therapeutics
Published: March 07, 2026
Last Updated: 04/28/2026